The effect of bupropion XL and escitalopram on memory and functional outcomes in adults with major depressive disorder: Results from a randomized controlled trial

Psychiatry Research

Volumn 220, Issue 1-2, 2014, Pages 245-250

  Soczynska, Joanna K ^a,b   Ravindran, Lakshmi N ^b,c,d   Styra, Rima ^b,c   McIntyre, Roger S ^a,b,c   Cyriac, Anna ^b   Manierka, Marena S ^c   Kennedy, Sidney H ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

Bupropion XL; Clinical trial; Cognition; Escitalopram; Functional outcomes; Major depressive disorder; Memory

Indexed keywords

AMFEBUTAMONE; ESCITALOPRAM; ANTIDEPRESSANT AGENT; CITALOPRAM;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; ENDICOTT WORK PRODUCTIVITY SCALE; FEMALE; FUNCTIONAL STATUS; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; MALE; MEMORY; MOTIVATION AND ENERGY INVENTORY SHORT FORM; PRODUCTIVITY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RECALL; SHEEHAN DISABILITY SCALE; VERBAL MEMORY; WORKING MEMORY; ADOLESCENT; COGNITION; DEPRESSIVE DISORDER, MAJOR; DRUG EFFECTS; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGY; SHORT TERM MEMORY; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BUPROPION; CITALOPRAM; COGNITION; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MEMORY; MEMORY, SHORT-TERM; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84908241686     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2014.06.053     Document Type: Article

References (55)

1. Barrickman L.L., Perry P.J., Allen A.J., Kuperman S., Arndt S.V., Herrmann K.J., Schumacher E. Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry 1995, 34:649-657.
2. Baune B.T., Miller R., McAfoose J., Johnson M., Quirk F., Mitchell.D. The role of cognitive impairment in general functioning in major depression. Psychiatry Research 2010, 176:183-189.
3. Benedict R.H.B. Brief Visuospatial Memory Test-Revised 2005, Psychological Assessment Resources, Lutz, FL.
4. Biringer E., Rongve A., Lund.A. A review of modern antidepressants' effects on neurocognitive function. Current Psychiatry Reviews 2009, 5:164-174.
5. Bora E., Harrison B., Yücel M., Pantelis.C. Cognitive impairment in euthymic major depressive disorder: a meta-analysis. Psychological Medicine 2012, 1-10.
6. Bouffard B. Memory Performance of younger adult outpatients with major depressive disorder before and after antidepressant treatment 2009, (Ref. Type: (Thesis/Dissertation), York University, Toronto, Ontario.
7. Braw Y., Aviram S., Bloch Y., Levkovitz.Y. The effect of age on frontal lobe related cognitive functions of unmedicated depressed patients. Journal of Affective Disorders 2011, 129:342-347.
8. Buist-Bouwman M.A., Ormel J., de G.R., de J.P., van S.E., Alonso J., Bruffaerts R., Vollebergh W.A. Mediators of the association between depression and role functioning. Acta Psychiatrica Scandinavica 2008, 118:451-458.
9. Carvalho A.F., Köhler C.A., Cruz E.P., Sturmer P.L., Reichman B.P., Barea B.M., Izquierdo I., Chaves.M.L. Acute treatment with the antidepressants bupropion and sertraline do not influence memory retrieval in man. European Archives of Psychiatry and Clinical Neuroscience 2006, 256:320-325.
10. Chamberlain S.R., Müller U., Blackwell A.D., Clark L., Robbins T.W., Sahakian.B.J. Neurochemical modulation of response inhibition and probabilistic learning in humans. Science 2006, 311:861-863.
11. Chevassus H., Farret A., Gagnol J.P., Ponçon C.A., Costa F., Roux C., Galtier F., Petit.P. Psychological and physiological effects of bupropion compared to methylphenidate after prolonged administration in healthy volunteers (NCT00285155). European Journal of Clinical Pharmacology 2013, 69:779-787.
12. Collins P.Y., Patel V., Joestl S.S., March D., Insel T.R., Daar A.S., Anderson W., Dhansay M.A., Phillips A., Shurin S., Walport M., Ewart W., Savill S.J., Bordin I.A., Costello E.J., Durkin M., Fairburn C., Glass R.I., Hall W., Huang Y., Hyman S.E., Jamison K., Kaaya S., Kapur S., Kleinman A., Ogunniyi A., Otero-Ojeda A., Poo M.M., Ravindranath V., Sahakian B.J., Saxena S., Singer P.A., Stein.D.J. Grand challenges in global mental health. Nature 2011, 475:27-30.
13. Conners C.K., Casat C.D., Gualtieri C.T., Weller E., Reader M., Reiss A., Weller R.A., Khayrallah M., Ascher.J. Bupropion hydrochloride in attention deficit disorder with hyperactivity. Journal of the American Academy of Child and Adolescent Psychiatry 1996, 35:1314-1321.
14. Delis D., Kaplan E., Kramer J., Ober B. California Verbal Learning Test-II [Manual] 2000, Psychological Corporation, San Antonio, TX.
15. Diaconescu A., Kramer E., Hermann C., Ma Y., Dhawan V., Chaly T., Eidelberg D., McIntosh A., Smith.G. Distinct functional networks associated with improvement of affective symptoms and cognitive function during citalopram treatment in geriatric depression. Human Brain Mapping 2011, 32:1677-1691.
16. Elgamal S., Denburg S., Marriott M., MacQueen.G. Clinical factors that predict cognitive function in patients with major depression. Canadian Journal of Psychiatry 2010, 55:653-661.
17. Endicott J., Nee.J. Endicott Work Productivity Scale (EWPS): a new measure to assess treatment effects. Psychopharmacology Bulletin 1997, 33:13-16.
18. Evins A., Cather C., Deckersbach T., Freudenreich O., Culhane M., Olm-Shipman C., Henderson D., Schoenfeld D., Goff D., Rigotti.N. A double-blind placebo-controlled trial of Bupropion sustained-release for smoking cessation in schizophrenia. Journal of Clinical Psychopharmacology 2005, 25:218-225.
19. Fehnel S., Bann C., Hogue S., Kwong W., Mahajan.S. The development and psychometric evaluation of the Motivation and Energy Inventory (MEI). Quality of Life Research 2004, 13:1321-1336.
20. Fossati P., Coyette F.o., Ergis A.M., Allilaire J.F.o. Influence of age and executive functioning on verbal memory of inpatients with depression. Journal of Affective Disorders 2002, 68:261-271.
21. Greer T.L., Sunderajan P., Grannemann B.D., Kurian B.T., Trivedi.M.H. Does duloxetine improve cognitive function independently of its antidepressant effect in patients with major depressive disorder and subjective reports of cognitive dysfunction?. Depression Research and Treatment 2014, 2014:627863.
22. Godard J., Baruch P., Grondin S., Lafleur M.F. Psychosocial and neurocognitive functioning in unipolar and bipolar depression: a 12-month prospective study. Psychiatry Research 2012, 196:145-153.
23. Gualtieri C., Johnson.L. Bupropion normalizes cognitive performance in patients with depression. Medscape General Medicine 2007, 9:22.
24. Gualtieri C., Johnson L., Benedict.K.B. Neurocognition in depression: patients on and off medication versus healthy comparison subjects. The Journal of Neuropsychiatry and Clinical Neurosciences 2006, 18:217-225.
25. Guy W. ECDEU Assessment Manual for Psychopharmacology 1976, US Government Printing Office, Rockville, Maryland. 2nd Edition.
26. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery, and Psychiatry 1960, 23:56-62.
27. Hammar A., Lund A., Hugdahl.K. Long-lasting cognitive impairment in unipolar major depression: a 6-month follow-up study. Psychiatry Research 2003, 118:189-196.
28. Hasselbalch B.J., Knorr U., Kessing.L.V. Cognitive impairment in the remitted state of unipolar depressive disorder: a systematic review. Journal of Affective Disorders 2011, 134:20-31.
29. Herrera-Guzmán I., Gudayol-Ferré E., Herrera-Abarca J.E., Herrera-Guzmán D., Montelongo-Pedraza P., Padrós Blázquez F., Peró-Cebollero M., Guàrdia-Olmos.J. Major Depressive Disorder in recovery and neuropsychological functioning: effects of selective serotonin reuptake inhibitor and dual inhibitor depression treatments on residual cognitive deficits in patients with Major Depressive Disorder in recovery. Journal of Affective Disorders 2010, 123:341-350.
30. Herrera-Guzmán I., Gudayol-Ferré E., Herrera-Guzmán D., Guàrdia-Olmos J., Hinojosa-Calvo E., Herrera-Abarca.J.E. Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on memory and mental processing speed in patients with major depressive disorder. Journal of Psychiatric Research 2009, 43:855-863.
31. Iosifescu D.V. The relation between mood, cognition and psychosocial functioning in psychiatric disorders. European Neuropsychopharmacology 2012, 22:S499-S504.
32. Jaeger J., Berns S., Uzelac S., Davis-Conway.S. Neurocognitive deficits and disability in major depressive disorder. Psychiatry Research 2006, 145:39-48.
33. Knorr U.B. The effect of selective serotonin reuptake inhibitors in healthy first-degree relatives of patients with major depressive disorder - an experimental medicine blinded controlled trial. Danish Medical Journal 2012, 59:B4426.
34. Lam R., Filteau M., Milev.R. Clinical effectiveness: the importance of psychosocial functioning outcomes. Journal of Affective Disorders 2011, 132:S9-S13.
35. Lee R.S.C., Lee R., Hermens D., Porter M.A., Redoblado-Hodge.M.A. A meta-analysis of cognitive deficits in first-episode Major Depressive Disorder. Journal of Affective Disorders 2012, 140:113-124.
36. Mannie Z.N., Barnes J., Bristow G.C., Harmer C.J., Cowen.P.J. Memory impairment in young women at increased risk of depression: influence of cortisol and 5-HTT genotype. Psychological Medicine 2009, 39:757-762.
37. Mur M., Portella M.J., Martinez-Aran A., Pifarre.J. Influence of clinical and neuropsychological variables on the psychosocial and occupational outcome of remitted bipolar patients. Psychopathology 2009, 42:148. (-56).
38. Porter R.J., Gallagher P., Thompson J.M., Young.A.H. Neurocognitive impairment in drug-free patients with major depressive disorder. British Journal of Psychiatry 2003, 182:214-220.
39. Ramos B., Arnsten.A. Adrenergic pharmacology and cognition: focus on the prefrontal cortex. Pharmacology and Therapeutics 2007, 113:523-536.
40. Rose E., Simonotto E., Spencer E., Ebmeier.K. The effects of escitalopram on working memory and brain activity in healthy adults during performance of the n-back task. Psychopharmacology 2006, 185:339-347.
41. Rothschild A.J., Raskin J., Wang C.N., Marangell L.B., Fava.M. The relationship between change in apathy and changes in cognition and functional outcomes in currently non-depressed SSRI-treated patients with major depressive disorder. Comprehensive Psychiatry 2014, 55:1-10.
42. Schilstrom B., Konradsson-Geuken A.s., Ivanov V., Gertow J., Feltmann K., Marcus M., Jardemark K., Svensson.T. Effects of S-citalopram, citalopram, and R-citalopram on the firing patterns of dopamine neurons in the ventral tegmental area, N-methyl-D-aspartate receptor-mediated transmission in the medial prefrontal cortex and cognitive function in the rat. Synapse 2011, 65:357-367.
43. Schmitt J., Kruizinga M., Riedel.W. Non-serotonergic pharmacological profiles and associated cognitive effects of serotonin reuptake inhibitors. Journal of Psychopharmacology 2001, 15:173-179.
44. Sheehan D., Harnett-Sheehan K., Raj.B. The measurement of disability. International Clinical Psychopharmacology 1996, 11(Suppl 3):S89-S95.
45. Sheehan D., Lecrubier Y., Sheehan K., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., Dunbar.G. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry 1998, 59(Suppl 20).
46. Stahl S., Pradko J., Haight B., Modell J., Rockett C., Learned-Coughlin.S. A review of the neuropharmacology of Bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Primary Care Companion to The Journal of Clinical Psychiatry 2004, 6:159-166.
47. Vance D.E., Roberson A.J., McGuinness T.M., Fazeli.P.L. How neuroplasticity and cognitive reserve protect cognitive functioning. Journal of Psychosocial Nursing and Mental Health Services 2010, 48:23-30.
48. Wechsler D. WMS-III Administration and Scoring Manual 1997, Psychological Corporation, San Antonio, TX.
49. Weiland-Fiedler P., Erickson K., Waldeck T., Luckenbaugh D., Pike D., Bonne O., Charney D.S., Neumeister.A. Evidence for continuing neuropsychological impairments in depression. Journal of Affective Disorders 2004, 82:253-258.
50. Wingen M., Langer S., Ramaekers.J. Verbal memory performance during subchronic challenge with a selective serotonergic and a mixed action antidepressant. Human Psychopharmarmacology 2006, 21:473-479.
51. Woods S.P., Delis D.C., Scott J.C., Kramer J.H., Holdnack.J.A. The California Verbal Learning Test: second edition: test-retest reliability, practice effects, and reliable change indices for the standard and alternate forms. Archives of Clinical Neuropsychology 2006, 21:413-420.
52. World Health Organization The Global Burden of Disease: 2004 Update 2008, WHO Press, Geneva.
53. Wroolie T., Williams K., Keller J., Zappert L., Shelton S., Kenna H., Reynolds M., Rasgon.N. Mood and neuropsychological changes in women with midlife depression treated with escitalopram. Journal of Clinical Psychopharmacology 2006, 26:361-366.
54. Zachary R. Shipley Institute of Living Scale: Revised Manual 2000, Western Psychological Services, Los Angeles.
55. Zhong H., Haddjeri N., Sanchez.C. Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter: a review of current understanding of its mechanism of action. Psychopharmacology 2012, 219:1-13.